Compare McKesson Corporation (MCK) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Vanguard Growth Index Fund ETF — how do they compare? McKesson Corporation trades at $899.06 (market cap $102.58B), while Vanguard Growth Index Fund ETF trades at $89. The key difference: McKesson Corporation pays a 0.43% dividend while Vanguard Growth Index Fund ETF pays none, and Vanguard Growth Index Fund ETF is trading nearer its 52-week high, McKesson Corporation nearer its low. Which is the better fit depends on your goals.
| MCK | VUG | |
|---|---|---|
Market Cap | $102.58B | — |
Sector | Health | Sector/Thematic |
52-Week High | $995.69 | $90.29 |
52-Week Low | $659.01 | $70.00 |
Enterprise Value | $109.12B | — |
Dividend Yield | 0.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $869.58, down 0.14% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with revenue growth to $359.05B in 2025 and consistent earnings beats, including Q2 2026 EPS of $9.93 versus $9.56 expected. Valuation metrics like P/E of 23.33 and P/S of 0.26 indicate reasonable pricing relative to peers. Recent news highlights Q1 2027 results exceeding expectations and raised full-year guidance, driven by specialty drug and oncology growth.
Outlook remains positive with 80% analyst buy ratings and a $1,000 consensus price target, suggesting 15% upside. Risks include thin net margins of 1.12% and high liabilities at $76.83B, which could pressure equity during economic downturns. Investors should focus on execution of raised guidance and margin improvements from cost efficiencies.
Vanguard Growth ETF (VUG) trades at $89.4, up 0.81% today, with a bullish technical signal driven by strong moving average support. Recent news highlights significant institutional buying interest, with multiple firms increasing stakes by over 500% in Q2 2026. The ETF focuses on large-cap growth stocks, offering broad exposure to innovative US companies.
Outlook remains positive given institutional accumulation and growth stock momentum, though an RSI of 95.06 on a 6-day basis indicates potential overbought conditions. Key risks include market volatility and sensitivity to interest rate changes, but long-term growth prospects appear solid based on historical performance and sector trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
